Adenocarcinoma of the small bowel at a single Korean institute: Management and prognosticators

Yong Wha Moon, SunYoung Rha, Sang Joon Shin, Hyun Chang, Hyo Sup Shim, Jae Kyung Roh

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: Small bowel adenocarcinoma (SBA) is a rare malignancy with a poor outcome. We evaluated the natural history of SBA at a single Korean institute. Methods: Medical records of 100 patients with SBA were reviewed for clinical characteristics, treatment patterns, outcomes, and prognostic factors. Results: The most common primary tumor site was the duodenum (82%). Seventy-four patients were diagnosed with stage III/IV disease (28/46 patients, respectively). Sixty-six patients had surgery (R0/R1/R2 in 32/2/32) without operation-related mortality. Of 34 R0/R1-resected patients, 16 received adjuvant chemotherapy. The dominant pattern of recurrence following R0/R1 resection was distant metastasis (29%; 10 of 34 patients). Thirty-four patients with advanced SBA received palliative chemotherapy, showing a response rate of 27.6% and a median progression-free survival of 3.8 months. The median overall survival for all patients and R0/R1-resected patients was 10.5 and 42.1 months, respectively. In multivariate analysis, lower stage, nonduodenal location, and R0/R1 resection were good independent prognostic factors. Conclusions: Early diagnosis is crucial to improve outcomes of SBA with respect to increasing resectability. Distant metastasis as a dominant pattern of recurrence suggests a potential role for adjuvant chemotherapy. Newer antitumor agents in advanced SBA should be evaluated considering the poor efficacy of current palliative chemotherapy.

Original languageEnglish
Pages (from-to)387-394
Number of pages8
JournalJournal of cancer research and clinical oncology
Volume136
Issue number3
DOIs
Publication statusPublished - 2010 Mar 1

Fingerprint

Adenocarcinoma
Adjuvant Chemotherapy
Neoplasm Metastasis
Recurrence
Drug Therapy
Natural History
Duodenum
Antineoplastic Agents
Disease-Free Survival
Medical Records
Early Diagnosis
Neoplasms
Multivariate Analysis
Survival
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Moon, Yong Wha ; Rha, SunYoung ; Shin, Sang Joon ; Chang, Hyun ; Shim, Hyo Sup ; Roh, Jae Kyung. / Adenocarcinoma of the small bowel at a single Korean institute : Management and prognosticators. In: Journal of cancer research and clinical oncology. 2010 ; Vol. 136, No. 3. pp. 387-394.
@article{38666e9600134256b392db144972d5b2,
title = "Adenocarcinoma of the small bowel at a single Korean institute: Management and prognosticators",
abstract = "Purpose: Small bowel adenocarcinoma (SBA) is a rare malignancy with a poor outcome. We evaluated the natural history of SBA at a single Korean institute. Methods: Medical records of 100 patients with SBA were reviewed for clinical characteristics, treatment patterns, outcomes, and prognostic factors. Results: The most common primary tumor site was the duodenum (82{\%}). Seventy-four patients were diagnosed with stage III/IV disease (28/46 patients, respectively). Sixty-six patients had surgery (R0/R1/R2 in 32/2/32) without operation-related mortality. Of 34 R0/R1-resected patients, 16 received adjuvant chemotherapy. The dominant pattern of recurrence following R0/R1 resection was distant metastasis (29{\%}; 10 of 34 patients). Thirty-four patients with advanced SBA received palliative chemotherapy, showing a response rate of 27.6{\%} and a median progression-free survival of 3.8 months. The median overall survival for all patients and R0/R1-resected patients was 10.5 and 42.1 months, respectively. In multivariate analysis, lower stage, nonduodenal location, and R0/R1 resection were good independent prognostic factors. Conclusions: Early diagnosis is crucial to improve outcomes of SBA with respect to increasing resectability. Distant metastasis as a dominant pattern of recurrence suggests a potential role for adjuvant chemotherapy. Newer antitumor agents in advanced SBA should be evaluated considering the poor efficacy of current palliative chemotherapy.",
author = "Moon, {Yong Wha} and SunYoung Rha and Shin, {Sang Joon} and Hyun Chang and Shim, {Hyo Sup} and Roh, {Jae Kyung}",
year = "2010",
month = "3",
day = "1",
doi = "10.1007/s00432-009-0668-3",
language = "English",
volume = "136",
pages = "387--394",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "3",

}

Adenocarcinoma of the small bowel at a single Korean institute : Management and prognosticators. / Moon, Yong Wha; Rha, SunYoung; Shin, Sang Joon; Chang, Hyun; Shim, Hyo Sup; Roh, Jae Kyung.

In: Journal of cancer research and clinical oncology, Vol. 136, No. 3, 01.03.2010, p. 387-394.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adenocarcinoma of the small bowel at a single Korean institute

T2 - Management and prognosticators

AU - Moon, Yong Wha

AU - Rha, SunYoung

AU - Shin, Sang Joon

AU - Chang, Hyun

AU - Shim, Hyo Sup

AU - Roh, Jae Kyung

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Purpose: Small bowel adenocarcinoma (SBA) is a rare malignancy with a poor outcome. We evaluated the natural history of SBA at a single Korean institute. Methods: Medical records of 100 patients with SBA were reviewed for clinical characteristics, treatment patterns, outcomes, and prognostic factors. Results: The most common primary tumor site was the duodenum (82%). Seventy-four patients were diagnosed with stage III/IV disease (28/46 patients, respectively). Sixty-six patients had surgery (R0/R1/R2 in 32/2/32) without operation-related mortality. Of 34 R0/R1-resected patients, 16 received adjuvant chemotherapy. The dominant pattern of recurrence following R0/R1 resection was distant metastasis (29%; 10 of 34 patients). Thirty-four patients with advanced SBA received palliative chemotherapy, showing a response rate of 27.6% and a median progression-free survival of 3.8 months. The median overall survival for all patients and R0/R1-resected patients was 10.5 and 42.1 months, respectively. In multivariate analysis, lower stage, nonduodenal location, and R0/R1 resection were good independent prognostic factors. Conclusions: Early diagnosis is crucial to improve outcomes of SBA with respect to increasing resectability. Distant metastasis as a dominant pattern of recurrence suggests a potential role for adjuvant chemotherapy. Newer antitumor agents in advanced SBA should be evaluated considering the poor efficacy of current palliative chemotherapy.

AB - Purpose: Small bowel adenocarcinoma (SBA) is a rare malignancy with a poor outcome. We evaluated the natural history of SBA at a single Korean institute. Methods: Medical records of 100 patients with SBA were reviewed for clinical characteristics, treatment patterns, outcomes, and prognostic factors. Results: The most common primary tumor site was the duodenum (82%). Seventy-four patients were diagnosed with stage III/IV disease (28/46 patients, respectively). Sixty-six patients had surgery (R0/R1/R2 in 32/2/32) without operation-related mortality. Of 34 R0/R1-resected patients, 16 received adjuvant chemotherapy. The dominant pattern of recurrence following R0/R1 resection was distant metastasis (29%; 10 of 34 patients). Thirty-four patients with advanced SBA received palliative chemotherapy, showing a response rate of 27.6% and a median progression-free survival of 3.8 months. The median overall survival for all patients and R0/R1-resected patients was 10.5 and 42.1 months, respectively. In multivariate analysis, lower stage, nonduodenal location, and R0/R1 resection were good independent prognostic factors. Conclusions: Early diagnosis is crucial to improve outcomes of SBA with respect to increasing resectability. Distant metastasis as a dominant pattern of recurrence suggests a potential role for adjuvant chemotherapy. Newer antitumor agents in advanced SBA should be evaluated considering the poor efficacy of current palliative chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=77449112408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449112408&partnerID=8YFLogxK

U2 - 10.1007/s00432-009-0668-3

DO - 10.1007/s00432-009-0668-3

M3 - Article

C2 - 19760196

AN - SCOPUS:77449112408

VL - 136

SP - 387

EP - 394

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 3

ER -